BDX
NEUTRAL
$156.41
Live
Becton, Dickinson and Company · NYSE
Target $196.08
(+25.4%)
$127.59
52W Range
$187.35
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 01, 2026
Market cap
$56.67B
P/E
25.56
ROE
7.0%
Profit margin
8.0%
Debt/Equity
0.77
Dividend yield
2.67%
AI Analysis
AI-powered fundamental assessment
Confidence
90%
BDX shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Mixed signals with both opportunities and risks present.
Key Strengths
Company has established market presence
Key Risks
Limited historical data available for full assessment
AI Fair Value Estimate
Based on comprehensive analysis
$180.54
+15.4% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
52
Moderate
50
60
50
50
50
AI Verdict
BDX shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Mixed signals with both opportunities and risks present.
Key drivers: Company has established market presence, Limited historical data available for full assessment
Confidence
50%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
- Trades above Graham Number.
Future
60/100
Rule-based growth outlook.
Positives
- Growth-implied value exceeds price.
Watchpoints
No urgent risks highlighted.
Past
50/100
Historical performance + price trend: Shares moved -8.2% over 5Y and -9.9% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Health
50/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
50/100
Dividend policy fallback.
Positives
- Moderate dividend profile (Score: 50/100).
- Yield: 2.7%.
Watchpoints
No urgent risks highlighted.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$156.41
Analyst Target
$196.08
Upside/Downside
+25.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BDX and closest competitors.
Updated 2026-04-01
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BDX
Becton, Dickinson and Company
Primary
|
-8.2% | -14.8% | -9.9% | +5.4% | -10.8% | -1.2% |
|
IDXX
IDEXX Laboratories, Inc.
Peer
|
+51.5% | +58.8% | +62.9% | +33.2% | +7.9% | -2.6% |
|
ZTS
Zoetis Inc.
Peer
|
-23.5% | -16.7% | -29.9% | -25.4% | -14.7% | +0.5% |
|
EW
Edwards Lifesciences Corporation
Peer
|
+5.0% | +13.6% | +30.4% | +10.6% | +18.3% | +3.5% |
|
CAH
Cardinal Health, Inc.
Peer
|
+270.8% | +159.6% | +48.8% | +24.1% | -5.2% | -6.6% |
BDX
Becton, Dickinson and Company
Primary
5Y
-8.2%
3Y
-14.8%
1Y
-9.9%
6M
+5.4%
1M
-10.8%
1W
-1.2%
IDX
IDEXX Laboratories, Inc.
Peer
5Y
+51.5%
3Y
+58.8%
1Y
+62.9%
6M
+33.2%
1M
+7.9%
1W
-2.6%
ZTS
Zoetis Inc.
Peer
5Y
-23.5%
3Y
-16.7%
1Y
-29.9%
6M
-25.4%
1M
-14.7%
1W
+0.5%
EW
Edwards Lifesciences Corporation
Peer
5Y
+5.0%
3Y
+13.6%
1Y
+30.4%
6M
+10.6%
1M
+18.3%
1W
+3.5%
CAH
Cardinal Health, Inc.
Peer
5Y
+270.8%
3Y
+159.6%
1Y
+48.8%
6M
+24.1%
1M
-5.2%
1W
-6.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
25.56
Forward P/E
11.57
PEG Ratio
N/A
P/B Ratio
1.76
P/S Ratio
2.58
EV/Revenue
2.9
EV/EBITDA
10.52
Market Cap
$56.67B
Profitability
Profit margins and return metrics
Profit Margin
8.01%
Operating Margin
13.35%
Gross Margin
46.78%
ROE
6.96%
ROA
4.08%
Growth
Revenue and earnings growth rates
Revenue Growth
+1.6%
Earnings Growth
+28.6%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+26.1%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.77
Moderate
Current Ratio
1.05
Good
Quick Ratio
0.37
Poor
Cash/Share
$2.64
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$5.3B
Gross Margin
45.9%
Op. Margin
12.6%
Net Margin
7.3%
Total Assets
$54.8B
Liabilities
$29.6B
Equity
$25.3B
Debt/Equity
1.17x
Operating CF
$0.7B
CapEx
$-0.1B
Free Cash Flow
$0.5B
FCF Yield
84%
Healthcare Sector Comparison
Comparing BDX against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
25.56
This Stock
vs
75.44
Sector Avg
-66.1%
(Discount)
Return on Equity (ROE)
6.96%
This Stock
vs
-88.14%
Sector Avg
-107.9%
(Below Avg)
Profit Margin
8.01%
This Stock
vs
-16.28%
Sector Avg
-149.2%
(Weaker)
Debt to Equity
0.77
This Stock
vs
2.66
Sector Avg
-71.0%
(Less Debt)
Revenue Growth
1.6%
This Stock
vs
124.04%
Sector Avg
-98.7%
(Slower)
Current Ratio
1.05
This Stock
vs
4.47
Sector Avg
-76.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BDX
Becton, Dickinson and Company
|
NEUTRAL | $56.67B | 25.56 | 7.0% | 8.0% | $156.41 | |
|
IDXX
IDEXX Laboratories, Inc.
|
BULLISH | $56.01B | 54.63 | 64.6% | 24.7% | $689.93 | Compare |
|
ZTS
Zoetis Inc.
|
BULLISH | $53.39B | 20.34 | 49.9% | 28.2% | $120.82 | Compare |
|
EW
Edwards Lifesciences Corporation
|
NEUTRAL | $50.08B | 37.85 | 13.5% | 23.2% | $86.3 | Compare |
|
CAH
Cardinal Health, Inc.
|
NEUTRAL | $47.03B | 28.76 | -% | 0.7% | $199.85 | Compare |
BDX
Becton,...
NEUTRAL
Mkt Cap
$56.7B
P/E
25.6
ROE
7.0%
Price
$156.41
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-26 | FELD MICHAEL | Officer | Sale | 75 | $11,762 |
| 2026-03-16 | MINNIX LANESHA | General Counsel | Stock Award | 7,492 | - |
| 2026-03-02 | SPIKNER PAMELA L | Officer | Stock Award | 931 | - |
| 2026-03-02 | ROQUE VITOR | Chief Financial Officer | Stock Award | 931 | - |
| 2026-02-26 | FELD MICHAEL | Officer | Sale | 75 | $13,638 |
| 2026-02-18 | SCOTT BERTRAM LEE | Director | Sale | 953 | $174,027 |
| 2026-01-27 | BROWN WILLIAM M. | Director | Stock Award | 1,098 | - |
| 2026-01-27 | SCOTT BERTRAM LEE | Director | Stock Award | 1,098 | - |
| 2026-01-27 | JONES CHRISTOPHER IAN MONTAGUE | Director | Stock Award | 1,098 | - |
| 2026-01-27 | HENDERSON JEFFREY WILLIAM | Director | Stock Award | 1,098 | - |
| 2026-01-27 | ECKERT ROBERT ANDREW | Director | Stock Award | 1,098 | - |
| 2026-01-27 | RING TIMOTHY M | Director | Stock Award | 1,098 | - |
| 2026-01-27 | HAYES GREGORY J | Director | Stock Award | 1,098 | - |
| 2026-01-27 | WALDSTREICHER JOANNE | Director | Stock Award | 1,098 | - |
| 2026-01-27 | WRIGHT JACQUELINE | Director | Stock Award | 1,098 | - |
FELD MICHAEL
Officer
2026-03-26
75 shares
·
$11,762
MINNIX LANESHA
General Counsel
2026-03-16
7,492 shares
SPIKNER PAMELA L
Officer
2026-03-02
931 shares
ROQUE VITOR
Chief Financial Officer
2026-03-02
931 shares
FELD MICHAEL
Officer
2026-02-26
75 shares
·
$13,638
SCOTT BERTRAM LEE
Director
2026-02-18
953 shares
·
$174,027
BROWN WILLIAM M.
Director
2026-01-27
1,098 shares
SCOTT BERTRAM LEE
Director
2026-01-27
1,098 shares
JONES CHRISTOPHER IAN MONTAGUE
Director
2026-01-27
1,098 shares
HENDERSON JEFFREY WILLIAM
Director
2026-01-27
1,098 shares
ECKERT ROBERT ANDREW
Director
2026-01-27
1,098 shares
RING TIMOTHY M
Director
2026-01-27
1,098 shares
HAYES GREGORY J
Director
2026-01-27
1,098 shares
WALDSTREICHER JOANNE
Director
2026-01-27
1,098 shares
WRIGHT JACQUELINE
Director
2026-01-27
1,098 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
12 analysts
Argus Research
2026-03-23
Buy
Buy
Citigroup
2026-02-11
Buy
Buy
JP Morgan
2026-02-10
Neutral
Neutral
Jefferies
2026-02-10
Buy
Buy
RBC Capital
2026-02-10
Sector Perform
Sector Perform
Citigroup
2026-02-10
Buy
Buy
Piper Sandler
2026-02-10
Neutral
Neutral
Wells Fargo
2026-02-10
Equal-Weight
Equal-Weight
Piper Sandler
2026-01-28
Neutral
Neutral
Stifel
2026-01-07
Buy
Buy
Past News Coverage
Recent headlines mentioning BDX from our newsroom.
Newest → oldest
No matching news yet.